Smoothened Homolog (Protein Gx or SMO) - Pipeline Review, H2 2018

  • ID: 4590314
  • Drug Pipelines
  • 77 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • BeiGene Ltd
  • Genentech Inc
  • Ignyta Inc
  • IMPACT Therapeutics Inc
  • Mayne Pharma Group Ltd
  • Pfizer Inc
  • MORE
Smoothened Homolog (Protein Gx or SMO) - Pipeline Review, H2 2018

Summary:

Smoothened Homolog (Protein Gx or SMO) - Smoothened homolog (SMO) is a G protein-coupled receptor that probably associates with the patched protein (PTCH) to transduce the hedgehog's proteins signal. Binding of sonic hedgehog (SHH) to its receptor is thought to prevent normal inhibition by patched of smoothened (SMO). It is required for the accumulation of KIF7 and GLI3 in the cilia.

Smoothened Homolog (Protein Gx or SMO) pipeline Target constitutes close to 12 molecules. Out of which approximately 9 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Preclinical and Discovery stages are 2, 1, 3, 2 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.

Report covers products from therapy areas Oncology, Genetic Disorders, Gastrointestinal, Infectious Disease and Undisclosed which include indications Medulloblastoma, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Adenocarcinoma Of The Gastroesophageal Junction, Basal Cell Carcinoma (Basal Cell Epithelioma), Epithelial Ovarian Cancer, Fallopian Tube Cancer, Gorlin Syndrome (Basal Cell Nevus Syndrome), Peritoneal Cancer, Aspergillosis, Blastomycosis, Cirrhosis, Colon Cancer, Esophageal Cancer, Glioblastoma Multiforme (GBM), Histoplasmosis, Leukemias, Meningioma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Hepatocellular Carcinoma (HCC), Myelodysplastic Syndrome, Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), Refractory Multiple Myeloma, Relapsed Multiple Myeloma and Small-Cell Lung Cancer.

The latest report Smoothened Homolog (Protein Gx or SMO) - Pipeline Review, H2 2018, outlays comprehensive information on the Smoothened Homolog (Protein Gx or SMO) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Smoothened Homolog (Protein Gx or SMO) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape for Smoothened Homolog (Protein Gx or SMO)
  • The report reviews Smoothened Homolog (Protein Gx or SMO) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Smoothened Homolog (Protein Gx or SMO) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Smoothened Homolog (Protein Gx or SMO) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Smoothened Homolog (Protein Gx or SMO) targeted therapeutics
Reasons for Purchase:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Smoothened Homolog (Protein Gx or SMO)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Smoothened Homolog (Protein Gx or SMO) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • BeiGene Ltd
  • Genentech Inc
  • Ignyta Inc
  • IMPACT Therapeutics Inc
  • Mayne Pharma Group Ltd
  • Pfizer Inc
  • MORE
Introduction

Report Coverage

Smoothened Homolog (Protein Gx or SMO) - Overview

Smoothened Homolog (Protein Gx or SMO) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Smoothened Homolog (Protein Gx or SMO) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Smoothened Homolog (Protein Gx or SMO) - Companies Involved in Therapeutics Development

BeiGene Ltd

Genentech Inc

Ignyta Inc

IMPACT Therapeutics Inc

Mayne Pharma Group Ltd

Pfizer Inc

Sun Pharma Advanced Research Company Ltd

Smoothened Homolog (Protein Gx or SMO) - Drug Profiles

glasdegib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GSA-10 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IMP-5471 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

itraconazole - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

patidegib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize Smoothened Homolog for Medulloblastoma and Colon Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Target SMO and HDAC for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize Smoothened (Smo) Receptor for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Smoothened Homolog for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sonidegib phosphate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

taladegib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

vismodegib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Smoothened Homolog (Protein Gx or SMO) - Dormant Products

Smoothened Homolog (Protein Gx or SMO) - Discontinued Products

Smoothened Homolog (Protein Gx or SMO) - Product Development Milestones

Featured News & Press Releases

Jun 27, 2018 : U.S. FDA Grants Priority Review for Pfizer’s New Drug Application for Glasdegib in Patients with Previously Untreated Acute Myeloid Leukemia

Jun 05, 2018 : HedgePath Pharmaceuticals Granted Meeting with FDA to Discuss SUBA BCCNS Trial Data and Regulatory Pathway

May 21, 2018 : HedgePath Pharmaceuticals Announces Additional Expanded Patent Coverage

May 14, 2018 : HedgePath Pharmaceuticals Announces Expanded Patent Coverage

May 02, 2018 : Mayne Pharma Announces FDA Acceptance of New Drug Application for Its Antifungal Suba-Itraconazole Capsule

Jan 11, 2018 : HedgePath Pharmaceuticals Receives Orphan Drug Designation for SUBA-Itraconazole from the European Medicines Agency

Nov 20, 2017: FDA Grants Breakthrough Therapy Designation and Orphan Drug Designation to Pellepharm for Topical Patidegib in Gorlin Syndrome

Oct 30, 2017: HedgePath Pharmaceuticals Completes Enrollment for its Phase 2(b) Trial in BCCNS and Provides Trial Update

Sep 20, 2017: Sun Pharma Odomzo New Label Approval Shows Sustained Duration of Response of 26 Months in Treatment of Locally Advanced Basal Cell Carcinoma

Jul 31, 2017: PellePharm Announces Topline Results from Phase 2 Study of Topical Patidegib in Gorlin Syndrome Basal Cell Carcinomas

Jul 25, 2017: HedgePath Pharmaceuticals Receives Clarity From FDA Regarding Pathway to Potential Regulatory Submission

May 30, 2017: HedgePath Pharmaceuticals Announces Granting of Type-C Meeting Request by FDA and Provides Positive Clinical Trial Update

Dec 08, 2016: PellePharm Launches with Financing from BridgeBio Pharma to Develop Topical Therapy for Basal Cell Carcinomas and Gorlin Syndrome

Dec 03, 2016: New Phase 2 Results Show Investigational Compound Glasdegib Improved Overall Survival in Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome

Nov 28, 2016: Curis Announces Full Approval of Roche’s Erivedge® in the European Union

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Indications, H2 2018

Number of Products under Development by Indications, H2 2018 (Contd..1), H2 2018

Number of Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Products under Development by Companies, H2 2018 (Contd..2), H2 2018

Number of Products under Investigation by Universities/Institutes, H2 2018

Products under Investigation by Universities/Institutes, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Pipeline by BeiGene Ltd, H2 2018

Pipeline by Genentech Inc, H2 2018

Pipeline by Ignyta Inc, H2 2018

Pipeline by IMPACT Therapeutics Inc, H2 2018

Pipeline by Mayne Pharma Group Ltd, H2 2018

Pipeline by Pfizer Inc, H2 2018

Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2018

Dormant Products, H2 2018

Dormant Products, H2 2018 (Contd..1), H2 2018

Dormant Products, H2 2018 (Contd..2), H2 2018

Discontinued Products, H2 2018

List of Figures

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Top 10 Indications, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • BeiGene Ltd
  • Genentech Inc
  • Ignyta Inc
  • IMPACT Therapeutics Inc
  • Mayne Pharma Group Ltd
  • Pfizer Inc
  • Sun Pharma Advanced Research Company Ltd
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll